



SINCLAIR PHARMA STRENGTHENS BOARD

PENNY FREER APPOINTED TO THE BOARD

Godalming, UK; 25 January, 2006: Sinclair Pharma plc ("Sinclair" and the "Company"), the pharmaceutical company focused on the acquisition, development and out-licensing of niche patented products, today announces the appointment of Penny Freer as Non-executive Director with immediate effect.

Penny has been involved in small and mid-cap investment banking for almost 20 years, most recently as Head of Equities in London for Robert W Baird, the US investment bank. Penny was previously responsible for Credit Lyonnais' small and mid-cap equities activities.

The following disclosures are being made under paragraph (g) of Schedule 2 of the AIM Rules.

Current and Previous Directorships:

Current

Capital Markets Strategy Limited
Capital Markets Analysis Limited
The Capital Markets Group Limited
Empresaria Group plc
Peacock Blue Limited
Pilotfish Marine AB

In last five years

Robert W Baird Limited
Robert W Baird Group Limited
Wilton Wright Limited

Penny Freer has no interest in any ordinary shares in the Company.

There are no other matters which are required to be announced with regards to this appointment under paragraph (g) of Schedule 2 of the AIM Rules.

Commenting on the appointment, Steve Harris, Chairman of Sinclair Pharma, said: "I am delighted to welcome Penny to the Board of Sinclair. In her previous role at R.W. Baird she provided invaluable capital markets and industry advice as an advisor to Sinclair. We now look forward to her bringing her experience and insight to the Board as we advance the Company and product pipeline."

ENDS

Contact details:

Sinclair Pharma plc

Dr Michael Flynn, CEO
Tel: 01483 426 6444

Financial Dynamics

Ben Atwell, Tel. 0207 831 3113